AstraZeneca Targets $400B Bristol Myers Squibb Merger Twelve Years After Spurning Pfizer
AstraZeneca — the British pharmaceutical giant that famously rebuffed a $118 billion hostile takeover from Pfizer in 2014 by pledging to remain fiercely independent — is now reportedly pursuing a cross-Atlantic merger that would dwarf that very bid. The …